Low utilization of vancomycin in febrile neutropenia: real-world evidence from 4 Brazilian centers.
Jessica Fernandes RamosAndré Domingues PereiraMaria Cristina Nunez SeiwaldLarissa Simão GandolphoVinicius Campos MollaMariana GuaranáSimone A NouérMarcio NucciCelso Arrais RodriguesPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2023)
The results of this study underscore the notably low utilization rate of vancomycin in cases of febrile neutropenia, despite clear indications outlined in established guidelines. These findings emphasize the importance of carefully implementing guideline recommendations, considering local epidemiological factors, especially when the strength of recommendation is weak.